Lupin wins first FDA approval for generic version of Boehringer Ingelheim blockbuster Spiriva
Indian drugmaker Lupin today said it won FDA approval for the first generic version of Spiriva, a blockbuster COPD drug from Boehringer Ingelheim.
The generic, known as tiotropium bromide inhalation powder, first won approval as a brand name product in 2004 as a maintenance treatment for COPD-related breathing problems, before expanding its label five years later to reduce COPD exacerbations.
Spiriva — sold in a capsule form and delivered via an inhaler system — made Boehringer Ingelheim $1.7 billion last year, according to its annual report.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
